No abstract

Background and purpose:13 C-urea may be a suitable marker to assess the in vivo fate of colon-targeted dosage forms given by mouth. We postulated that release in the colon (urease-rich segment) of 13 C-urea from colon-targeted capsules would lead to fermentation of Conclusions and implications:In this proof-of-concept study, 13 C-urea was able to provide information on both the release kinetics of a colon-targeted oral dosage form and the gastrointestinal segment where it was released.